Purchase this article with an account.
D Pawlak, A Glacet-Bernard, W Roquet, G Coscas, G Soubrane; Photodynamic Therapy Or Macular Translocation For Subfoveal Choroidal Neovascularization In Age-related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3534.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To compare the visual outcome of a demonstated treatment of subfoveal classic neovascularization in age-related macular degeneration (AMD), photodynamic therapy (PDT), to a treatment under evaluation, limited macular translocation (LMT). Methods: A retrospective review was conducted on a consecutive series of 60 eyes of 60 patients with subfoveal neovascularization due to AMD: 28 were treated by PDT with verteporfin, 32 underwent LMT with scleral imbrication . The follow-up was at least 6 months. The main outcome criteria were final best-corrected visual acuity and a 2 lines or more change in visual acuity. Results: Both groups were similar for age, refraction, and the size of the neovascular membrane (mean, 950µm). The initial visual acuity was lower in the translocation group than in the PDT group (20/200 versus 20/100). The average displacement in the LMT group was 940µm (range, 250 to 1,900µm). The number of retreatment in the PDT group was in average 2.5. Mean follow-up was 9,4 months. At the end of follow-up, the change in visual acuity was more favorable in the translocation group than in the PDT group: vision was stable in the translocation group whereas eyes of the PDT group experienced a decrease of in average more than 2.5 lines. Nevertheless, due to the initial level of visual acuity, the PDT group had a better final visual acuity (20/160) than the translocation group (20/250). Conclusion: In this retrospective study, macular translocation seems to preserve visual acuity better than PDT in subfoveal neovascularization due to AMD. Further larger and controlled studies are required to evaluate the best indications for both treatments.
This PDF is available to Subscribers Only